Ramucirumab — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

3 Recruiting

9 Completed trials

10 Sponsors

17 Countries

Phase III

Phase II

Phase I/II

Phase III: 5 Phase II/III: 1 Phase II: 5 Phase I/II: 3

Oversight events:

1 serious breach 1 temporary halt 1 unexpected event 9 corrective measures across 3 trials

View oversight register →

Indications tested

Colorectal cancer metastatic 1 Non-small cell lung cancer metastatic 1 Non-small cell lung cancer 1

Sponsors using this IMP

AstraZeneca AB 4 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 2 Affimed GmbH 1 Alx Oncology Inc. 1 Daiichi Sankyo Inc. 1 Eli Lilly & Co. 1 Fondation Franc.Cancerologie Digestive 1 Martin-Luther-Universitaet Halle-Wittenberg 1 Merck Sharp & Dohme LLC 1 Mirati Therapeutics Inc. 1

All trials

14 total

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending

2024-519786-22-01 Phase I/II 7 countries AstraZeneca AB
A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s… Pending

2025-524843-11-00 Phase II 3 countries AstraZeneca AB
Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting

2024-512484-31-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Volrustomig Priming Regimens Exploratory Phase II Platform Study Recruiting

2023-509482-20-00 Phase II 6 countries AstraZeneca AB
Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting

2023-509306-29-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Phase III 5 countries AstraZeneca AB
A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended

2023-509406-30-00 Phase II/III 5 countries Alx Oncology Inc.
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Phase III 15 countries Mirati Therapeutics Inc.
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended

2023-507963-20-00 Phase III 10 countries Daiichi Sankyo Inc.
PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advance… Ended

2024-513515-27-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended

2024-511999-32-00 Phase I/II 2 countries Affimed GmbH
A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastat… Ended

2024-515045-42-00 Phase II 1 country Martin-Luther-Universitaet Halle-Wittenberg
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 Phase III 3 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic… Ended

2024-514269-20-00 Phase III 1 country Eli Lilly & Co.

Showing 1–14 of 14 trials

← All drugs A–Z